<DOC>
	<DOCNO>NCT02840461</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , parallel-design , multiple-site clinical study evaluate therapeutic equivalence safety ivermectin cream 1 % ( Actavis Laboratories UT , Inc. ) SoolantraTM ( ivermectin ) cream 1 % ( Galderma ) treatment moderate severe papulopustular rosacea .</brief_summary>
	<brief_title>Clinical Endpoint Study Ivermectin 1 % Cream</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>1 . Signed Informed Consent meet criteria current FDA regulation . 2 . Healthy male nonpregnant , nonlactating female great equal 8 year age clinical diagnosis moderate severe papulopustular rosacea , define presence : A total 8 50 combined papules/pustules face , AND At least moderate erythema , AND Telangiectasia 3 . Patient baseline Investigator 's Global Evaluation ( IGE ) score 3 ( moderate ) 4 ( severe ) rosacea severity ( See Appendix A ) . 4 . Females child bear potential must pregnant lactate Screening ( confirm negative urine pregnancy test sensitivity le 25 mlU/mL equivalent unit human chorionic gonadotropin ) . Women childbearing potential must agree use reliable method contraception ( e.g. , total abstinence , IUD , doublebarrier method [ condom plus diaphragm spermicide ] , oral , transdermal , injected implant non hormonal contraceptive ) , throughout study . If female use hormonal contraceptive , product must take 3 month prior Visit 1 must agree replace hormonal contraceptive study . A sterile sexual partner consider adequate form birth control . All female consider childbearing potential unless : Are postmenopausal , define woman amenorrheic least 12 consecutive month , without know suspected primary cause . Have sterilize surgically otherwise prove sterile ( i.e. , total hysterectomy , bilateral oophorectomy ) surgery least 4 week Screening . Tubal ligation consider surgically sterile method . Female patient childbearing potential defined Women without prior hysterectomy least 4 week , evidence menses past 12 month . Females amenorrhea equal 12 month , amenorrhea possibly due cause , include prior chemotherapy , antiestrogens , ovarian suppression . 5 . Free systemic dermatologic disorder , opinion Investigator , interfere study result increase risk adverse event . 6 . Willing minimize external factor might trigger rosacea flareups ( e.g. , extreme temperature , aggressive astringent , know offend food spicy food thermally hot food drink , prolong sun exposure , strong wind , alcoholic beverage , emotional stress ) within 24 hour Screening visit . 7 . Of skin type race , provide skin pigmentation allow accurate evaluation papulopustular rosacea . 8 . Willingness capability cooperate extent degree require protocol . 1 . Females pregnant , lactate plan become pregnant study period . 2 . Patient mild facial rosacea ( le 8 inflammatory lesion face ) severe rosacea ( 50 inflammatory lesion ) . 3 . Patient mild erythema . 4 . Patient baseline IGE score 0 , 1 2 . 5 . Patient skin condition face would interfere diagnosis assessment rosacea ( e.g. , dermatitis , psoriasis , squamous cell carcinoma , eczema , acneform eruption cause medication , steroid acne , steroid folliculitis , bacterial folliculitis ) . 6 . Patients excessive facial hair , beard , sideburn , moustache , etc. , would interfere diagnosis assessment rosacea . 7 . Patients tattoos excessive facial scarring , Investigator 's opinion , may interfere evaluation patient 's rosacea . 8 . Patients active facial sunburn , peel sunburn , patient expose excessive sunlight study . 9 . Patient significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participation . 10 . Any patient ( male female ) start , change hormonal therapy within 3 month baseline visit ( include hormonal contraceptive ) . Patients stable hormone therapy least 3 month whose therapy consider unlikely change duration study eligible . 11 . History hypersensitivity allergy study drug , ingredient formulation . 12 . Use within 6 month prior baseline oral retinoids ( e.g. , Accutane ) therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) . 13 . Use le 3 month prior baseline estrogen and/or progestincontaining oral , injectable , implant , transdermal contraceptive ; use therapy must remain constant throughout study . 14 . Use within 1 month prior baseline 1 ) topical retinoids face , 2 ) systemic ( e.g. , oral injectable ) antibiotic know impact severity facial rosacea ( e.g. , contain tetracycline derivative , erythromycin derivative , sulfamethoxazole , trimethoprim ) , 3 ) systemic steroid , 4 ) photodynamic therapy ( include laser light therapy ) , 6 ) cosmetic procedure ( e.g. , superficial chemical peel , exfoliation microdermabrasion face ) . 15 . Use within 2 week prior baseline 1 ) topical corticosteroid , 2 ) topical antibiotic , 3 ) topical antiinflammatory agent 4 ) topical medication rosacea ( e.g. , metronidazole , azelaic acid , sodium sulfacetamide , ivermectin ) 5 ) immunosuppressive drug , 6 ) anticoagulant therapy . 16 . Use topical product apply target site . 17 . Use systemic corticosteroid . The use inhale corticosteroid le 1mg per day acceptable . 18 . Use antipruritic , include antihistamine , within 24 hour study visit . 19 . Patients use makeup must use brands/types minimum period 14 day study entry must agree change brand frequency use throughout study . 20 . Presence carcinoid , pheochromocytoma , cause systemic flushing . 21 . Presence acne conglobata , acne fulminans , secondary acne severe acne require systemic treatment . 22 . Ocular rosacea ( e.g. , conjunctivitis , blepharitis , keratitis ) sufficient severity require topical systemic antibiotic . 23 . Receipt drug part research study within 30 day dose . 24 . Employees research center Investigator . 25 . Patients illiterate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>